[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Caris Life Sciences Inc (CAI)

Caris Life Sciences Inc (CAI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 6,539,248
  • Shares Outstanding, K 282,595
  • Annual Sales, $ 812,030 K
  • Annual Income, $ -68,090 K
  • EBIT $ 153 M
  • EBITDA $ 189 M
  • 60-Month Beta 0.68
  • Price/Sales 8.14
  • Price/Cash Flow 14.68
  • Price/Book 11.18

Options Overview Details

View History
  • Implied Volatility 77.60% (+5.03%)
  • Historical Volatility 79.86%
  • IV Percentile 30%
  • IV Rank 30.34%
  • IV High 132.24% on 03/18/26
  • IV Low 53.81% on 01/21/26
  • Expected Move (DTE 9) 1.32 (5.92%)
  • Put/Call Vol Ratio 7.00
  • Today's Volume 104
  • Volume Avg (30-Day) 667
  • Put/Call OI Ratio 0.63
  • Today's Open Interest 15,552
  • Open Int (30-Day) 11,517
  • Expected Range 20.94 to 23.58

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 14 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $0.03
  • Number of Estimates 4
  • High Estimate $0.06
  • Low Estimate $0.01
  • Prior Year $0.08
  • Growth Rate Est. (year over year) -62.50%

Price Performance

See More
Period Period Low Period High Performance
1-Month
15.11 +47.32%
on 07/23/26
23.66 -5.92%
on 08/11/26
+5.27 (+31.02%)
since 07/10/26
3-Month
14.19 +56.87%
on 05/13/26
23.66 -5.92%
on 08/11/26
+5.50 (+32.82%)
since 05/12/26
52-Week
14.19 +56.87%
on 05/13/26
42.50 -47.62%
on 08/22/25
-10.20 (-31.42%)
since 08/12/25

Most Recent Stories

More News
Caris Life Sciences Reports Second Quarter 2026 Financial Results and Increases 2026 Revenue Guidance

Revenue growth of 45% driven by strong performance in molecular profiling services, including approximately 59,200 clinical cases, consisting of over 114,000 whole exome/whole transcriptome tests with...

CAI : 22.26 (-3.80%)
Caris Life Sciences Reports Tomorrow After Watching Its Stock Lose Half Its Value Since Launch

Barchart Research What to Expect from CAI Earnings CAI Generated August 4, 2026 Current Price $16.10 EPS Estimate $$-0.01 Consensus Rating Moderate Buy Average Move 8.68% Caris Life Sciences Reports Tomorrow...

CAI : 22.26 (-3.80%)
Caris Life Sciences to Report Second Quarter 2026 Financial Results on August 5, 2026

IRVING, Texas , July 16, 2026 /PRNewswire/ -- Caris Life Sciences ® (NASDAQ: CAI), a leading TechBio company, today announced it will report second quarter 2026 financial results on Wednesday,...

CAI : 22.26 (-3.80%)
Caris Life Sciences Expands Precision Oncology in Metastatic Prostate Cancer with PTEN IHC Testing

IRVING, Texas , July 14, 2026 /PRNewswire/ -- Caris Life Sciences ® (NASDAQ: CAI), a leading patient-centric next-generation AI TechBio company and precision medicine pioneer, today announced...

CAI : 22.26 (-3.80%)
Caris Life Sciences Announces Dual Listing on NYSE Texas

IRVING, Texas , June 16, 2026 /PRNewswire/ -- Caris Life Sciences ® (NASDAQ: CAI), a leading patient-centric next-generation AI TechBio company and precision medicine pioneer, today announced...

CAI : 22.26 (-3.80%)
Caris Life Sciences Announces Share Repurchase Program

IRVING, Texas , June 8, 2026 /PRNewswire/ -- Caris Life Sciences® (Nasdaq: CAI) ("Caris" or the "Company"), a leading next-generation AI TechBio company and precision medicine pioneer, today announced...

CAI : 22.26 (-3.80%)
Caris Life Sciences Launches Behind the Diagnosis Campaign Spotlighting Patient Lives Transformed by Caris' Comprehensive Genomic Testing

Inaugural story spotlights a woman whose presumed stage 4 metastatic breast cancer diagnosis was corrected by Caris GPSai, an AI-powered tissue-of-origin model, revealing a highly treatable lymphoma...

CAI : 22.26 (-3.80%)
You’ve Likely Never Heard of Caris Life Sciences Stock. Billionaire Stanley Druckenmiller Has – and He Likes What He Sees.

Caris Life Sciences just earned a $33.87 million vote of confidence from Stanley Druckenmiller, and most people completely missed it.

CAI : 22.26 (-3.80%)
Caris Life Sciences Publishes Study on the Caris Lookback Program Demonstrating the Ongoing Clinical Value of Comprehensive Testing with Caris MI Cancer Seek

The Caris Lookback Program identified 13,293 patients potentially eligible for newly approved targeted therapies across 10 tumor types

CAI : 22.26 (-3.80%)
Caris Life Sciences Eyes Bigger Oncology Market After IPO as Revenue Jumps 79%

Caris Life Sciences (NASDAQ:CAI) executives said the company is expanding its commercial reach, product pipeline and biopharma partnerships as it looks to build on recent revenue growth following its IPO...

CAI : 22.26 (-3.80%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Weakest short term outlook on maintaining the current direction.

Relative Strength is above 70%. The market is in overbought territory. Watch for a potential trend reversal.

See More Share

Business Summary

Caris Life Sciences Inc. provides diagnostics and anatomic pathology services. It develops an unbiased profiling platform for novel target identification, drug development and delivery, diagnostic and disease monitoring and precision medicine enabling aspects. Caris Life Sciences Inc. is based in Irving,...

See More

Key Turning Points

3rd Resistance Point 23.80
2nd Resistance Point 23.38
1st Resistance Point 22.82
Last Price 22.26
1st Support Level 21.84
2nd Support Level 21.43
3rd Support Level 20.87

See More

52-Week High 42.50
Fibonacci 61.8% 31.69
Fibonacci 50% 28.34
Fibonacci 38.2% 25.00
Last Price 22.26
52-Week Low 14.19

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.